What's next for Novo Nordisk's anti-obesity drug CagriSema?
A version of this article first appeared in CNBC's Healthy Returns newsletter, bringing the latest healthcare news directly to your…
iShares US Pharmaceuticals ETF
Eli Lilly launches anti-obesity drug Zepbound with one-month dosage
An Eli Lilly & Co. Zepbound injection pen placed in the Brooklyn borough of New York on March 28, 2024.…
Novo Nordisk Shares Fall as Weight Loss Drug Fails to Beat Eli Lilly
The Novo Nordisk A/S headquarters in Bagsvaerd, Denmark, on Wednesday, November 5, 2025. Nichlas Pollier | Bloomberg | fake images…